We are live on ! Find out more
NXTM

NxStage Medical Inc.
NXTM

Delisted

NXTM was delisted on the 21st of February, 2019.

175 hedge funds and large institutions have $1.61B invested in NxStage Medical Inc. in 2018 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 54 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 21

2% more funds holding

Funds holding: 171175 (+4)

1% more capital invested

Capital invested by funds: $1.59B → $1.61B (+$17.1M)

2% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 54

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

36% less call options, than puts

Call options by funds: $1.97M | Put options by funds: $3.08M

Holders
175
Holders Change
+4
Holders Change %
+2.34%
% of All Funds
4%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.14%
New
28
Increased
53
Reduced
54
Closed
21
Calls
$1.97M
Puts
$3.08M
Net Calls
-$1.11M
Net Calls Change
-$1.04M
Name Holding Trade Value Shares
Change
Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$15.6M +$3.32M +118,020 +27%
Wells Fargo
27
Wells Fargo
California
$15.5M -$194K -6,910 -1%
MCP
28
Moab Capital Partners
New York
$15.1M +$8.9M +316,362 +140%
Grantham, Mayo, Van Otterloo & Co (GMO)
29
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$14M -$14.5M -514,540 -51%
PCM
30
Pentwater Capital Management
Florida
$13.9M
FBCM
31
Fort Baker Capital Management
California
$13.1M +$20.9K +742 +0.2%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$11.9M +$291K +10,343 +2%
MP
33
Manikay Partners
New York
$11.9M +$12M +425,000 New
Charles Schwab
34
Charles Schwab
California
$10.1M +$334K +11,878 +3%
GCIA
35
Gabelli & Co Investment Advisers
New York
$9.89M +$394K +14,002 +4%
Allianz Asset Management
36
Allianz Asset Management
Germany
$9.48M
DCM
37
DAFNA Capital Management
California
$8.54M
Man Group
38
Man Group
United Kingdom
$8.46M -$1.3M -46,073 -13%
Canada Pension Plan Investment Board
39
Canada Pension Plan Investment Board
Ontario, Canada
$7.79M +$7.86M +279,400 New
SG Americas Securities
40
SG Americas Securities
New York
$7.67M +$7.37M +262,151 +2,037%
AGM
41
Alpine Global Management
New York
$7.66M -$1.13M -40,100 -13%
GF
42
Gabelli Funds
New York
$7.08M +$8.44K +300 +0.1%
Renaissance Technologies
43
Renaissance Technologies
New York
$7.01M +$2.56M +91,000 +57%
PAMU
44
Pictet Asset Management (UK)
United Kingdom
$6.65M +$938K +33,340 +16%
Alyeska Investment Group
45
Alyeska Investment Group
Illinois
$6.47M -$2.19M -77,933 -25%
AllianceBernstein
46
AllianceBernstein
Tennessee
$6.21M +$2.09M +74,490 +50%
Wellington Management Group
47
Wellington Management Group
Massachusetts
$5.78M +$2.33M +82,925 +67%
Capital Fund Management (CFM)
48
Capital Fund Management (CFM)
France
$5.42M
CS
49
Credit Suisse
Switzerland
$5.38M -$890K -31,649 -14%
OAC
50
OMERS Administration Corp
Ontario, Canada
$5.31M

NXTM Hedge Fund Activity: Q3 2018 in Review

175 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in NxStage Medical Inc. (NXTM) for Q3 2018, worth a combined $1.61B — up 1.1% from $1.59B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NXTM positions and 21 closed out — a net gain of 7 holders — while 53 added to existing stakes and 54 trimmed.

The largest buyer was Millennium Management, adding an estimated $34.3M. The largest seller was Flossbach Von Storch, cutting an estimated $46.7M.

  • 175 institutional investors held NxStage Medical Inc. (NXTM) as of Q3 2018, up from 171 in Q2 2018.
  • Funds reported $1.61B of NxStage Medical Inc. stock for Q3 2018, up 1.1% quarter-over-quarter.
  • 28 funds opened new NxStage Medical Inc. positions in Q3 2018 and 21 closed out, a net change of +7 holders.
  • The largest NxStage Medical Inc. buyer in Q3 2018 was Millennium Management, an estimated $34.3M added.
  • The largest NxStage Medical Inc. seller in Q3 2018 was Flossbach Von Storch, an estimated $46.7M sold.

Based on aggregated 13F filings for Q3 2018.